Topic: Generic Health Relevance and Cross Cutting Themes
Conditions
Interventions
1. Control group: women received no vitamin D supplementation (n = 60)
2. Daily Vitamin D: women received 800 IU of vitamin D (ergocalciferol) daily from 27 weeks gestation until delivery (n = 60)
3.
Sponsors
Imperial College London (UK)
Eligibility
Sex/Gender
All
Inclusion criteria
Inclusion criteria: All of the offspring of the 180 mothers recruited in the Vitamin D deficiency and supplementation during pregnancy trial are eligible and are invited to participate in this follow up study when their children are 3 years of age.
Exclusion criteria
Exclusion criteria: Severe congenital or developmental abnormalities likely to significantly affect respiratory health or lung function, e.g., congenital thoracic dystrophy.
Design outcomes
Primary
| Measure | Time frame |
|---|---|
| Percentage (%) of children with any wheezing episode in the first 3 years of life, measured at 36 - 48 months | — |
Secondary
| Measure | Time frame |
|---|---|
| All measured at 36 - 48 months: 1. % of children using inhaled bronchodilators in the last 12 months 2. % of children with doctor diagnosed rhinitis 3. % of children with any wheezing episode in the preceding 12 months 4. % of children with doctor diagnosed asthma 5. % of children with doctor diagnosed eczema 6. % of children with doctor diagnosed food allergy 7. % of children with positive skin prick test responses 8. 25-hydroxyvitamin D levels 9. Bronchodilator responsiveness 10. Exhaled nitric oxide level (in parts per billion) 11. Nasal secretions for inflammatory mediators 12. Pulmonary airflow resistance and reactance at a range of frequencies using impulse oscillometry 13. Total number of all wheezing episodes since birth 14. Total number of upper and lower respiratory tract infections since birth | — |
Countries
United Kingdom
Outcome results
None listed